IL-LANIFICIO
5.6.2024 09:01:33 CEST | Business Wire | Press release
Il Lanificio, the premium Italian apparel brand, is pleased to announce that it is opening two new stores in Pescara, Italy and Aubonne, Switzerland. These new openings will increase Il Lanificio’s total portfolio to 18 stores across Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240605960836/en/
The Pescara store will open on 7 June, with the Swiss store due to open in July, marking Il Lanificio’s third international outlet, joining existing locations in San Marino and Mendrisio, Switzerland and emphasising the brand's growing European presence.
Il Lanificio is a premium Italian apparel brand for men and women, known for its high-quality fabrics, exceptional tailoring and its commitment to deliver specialist, Italian craftsmanship direct to customers. The brand blends tradition with contemporary style, offering collections that cater to all demographics across outlets and online retail platforms. The new stores will be versatile, light and authentic, designed to embrace the customer with a warm welcome and communicate the quality and authenticity of its products. A new, multi-language e-commerce platform completes the customer omnichannel experience.
Since being acquired in 2018 by Njord Partners, Il Lanificio has benefitted from a renewed focus on its outlet business and an ambitious growth plan. Last year the Company grew its number of stores by 60% and its revenues by 40%. Il Lanificio intends to open up to 10 further stores in Europe by the end of 2025.
Filippo Vadda, CEO of Il Lanificio, commented: “Il Lanificio is internationally recognized as a high-quality apparel brand and the opening of these new stores underlines our commitment to growth both in Italy and internationally. We have doubled our number of outlets since 2021 and are excited to continue this expansion across Europe as we target the opening of six new stores this year, showcasing the best of our made-in-Italy offerings”.
Arvid Trolle, Partner at Njord Partners, said: “We are very pleased to see Il Lanificio go from strength to strength as an influential and growing apparel brand. Njord recognized the heritage and potential of the Il Lanificio brand and we are delighted that our investment in the business has ensured the sustainability and growth of the business. The company's performance and expansion are testament to the hard work and dedication of Il Lanificio’s team and we are excited by the promising future that lies ahead for us all.”
About Il Lanificio
Il Lanificio is an Italian outlet apparel brand of luxury made-in-Italy products. It is recognised by customers for having one of the best price-to-quality offers in the casual-chic and formal market. The first Il Lanificio retail store opened in 2002, and now has 15 stores across Italy, two in Switzerland and one in San Marino. Il Lanificio continues to grow whilst remaining focused on traditional design and excellent quality.
To find out more visit: https://www.illanificio.it/en/
About Njord Partners
Njord Partners is a special situations investment manager and provider of long-term flexible capital solutions. Established in 2013, Njord Partners manages capital in excess of €1 billion. Investing in European middle-market companies facing complex situations, its mission is to deliver superior risk-weighted returns to investors while preserving capital. As a capital partner, Njord Partners offers flexible debt and equity solutions, actively facilitating strategic and operational enhancements within its portfolio companies to drive value.
To find out more visit: https://njordpartners.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240605960836/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom